US EditionPublished • loading... • Updated
ManukaGuard: The end of the “medicated” nose
Summary by CDR – Chain Drug Review
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
ManukaGuard: The end of the “medicated” nose
MONTEREY, Calif. — ManukaGuard is establishing itself as a competitor to traditional respiratory care by promoting a move from symptom-focused treatment to routine nasal hygiene and barrier protection.The biotechnology company contends that modern strategies for nasal health are mostly reactive, addressing congestion, allergies, or infections only after the nasal cavity has been affected. According to ManukaGuard, common treatments like steroids…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
